The REACtiVe-2 trial will assess the safety and efficacy of CD40 agonist mitazalimab (Alligator Bioscience) in combination with MesoPher in patients with progressive metastatic pancreatic cancer. The first patient has been dosed in the phase I proof-of-concept trial that will enroll up to 18 patients. The investigator initiated trial will be performed at Erasmus Medical Center Rotterdam. The trial follows compelling pre-clinical data published in Journal for Immunotherapy of Cancer (Lau SP, et al. J Immunother Cancer 2020, link)